Additional data sets available

Global Alzheimer’s Association Interactive Network

GAAIN logo

The Global Alzheimer’s Association Interactive Network (GAAIN) is a big-data community for cohort discovery and data exploration that promotes data sharing among a federated, global network of data partners who are studying Alzheimer’s disease and other dementias. It is a collaborative project that provides researchers around the world with access to clinical, genetic, and imaging data on Alzheimer’s disease from hundreds of thousands of subject participants through compelling and intuitive graphical user interfaces. Led by Arthur Toga, PhD, Director of the Laboratory of Neuro Imaging (LONI) at the University of Southern California, GAAIN’s goal is to transform the way researchers work together to answer fundamental questions related to understanding the causes, diagnosis, treatment, and prevention of Alzheimer’s disease. To learn more and use GAAIN, visit

CERAD data

Please note that the CERAD data described below resulted from studies that were conducted independently of NACC; we serve only as a storage place.

Consortium to Establish a Registry for Alzheimer's Disease (CERAD): The first twenty years

Alzheimers Dement. 2008 Mar;4(2):96-109,PMID: 18631955

Gerda G. Fillenbaum, Gerald van Belle, John C. Morris, Richard C. Mohs, Suzanne S. Mirra, Patricia C. Davis, Pierre N. Tariot, Jeremy M. Silverman, Christopher M. Clark, Kathleen A. Welsh-Bohmer, Albert Heyman

ABSTRACT: The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) was funded by the National Institute on Aging in 1986 to develop standardized, validated measures for the assessment of Alzheimer's disease (AD). The present report describes the measures that CERAD developed during its first decade and their continued use in their original and translated forms. These measures include clinical, neuropsychological, neuropathologic, and behavioral assessments of AD and also assessment of family history and parkinsonism in AD. As approach to evaluating neuroimages did not meet the standards desired. Further evaluations that could not be completed because of lack of funding (but where some materials are available) include evaluation of very severe AD and of service use and need by patient and caregiver. The information that was developed in the U.S. and abroad permits standardized assessment of AD in clinical practice, facilitates epidemiologic studies, and provides information valuable for individual and public health planning. CERAD materials and data remain available for those wishing to use them.

More information about CERAD, including how to request data, can be found here.